FluoroPharma Medical Chairman & CEO to Present at 15th Annual B. Riley Conference on May 19th at 4:00 pm PDT

FluoroPharma Medical Chairman & CEO to Present at 15th Annual B. Riley Conference on May 19th at 4:00 pm PDT

Mr. Spoor's Presentation Will Also Be Webcast Live and Available for Replay

MONTCLAIR, NJ--(Marketwired - May 19, 2014) - FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, announced today that its Chairman & CEO, Thijs Spoor, will present at the 15th Annual B. Riley & Co. Investor Conference to be held at May 19th - 21st at the Loews Santa Monica Beach Hotel in Santa Monica, CA.

Mr. Spoor will present on Monday, May 19th at 4:00 pm PDT. The presentation will be webcast live and available for replay at http://www.brileyconference.com/2014/register/profile.php?ticker=FPMI.

About FluoroPharma Medical, Inc. FluoroPharma is a biopharmaceutical company engaged in the discovery and development of proprietary PET imaging products to evaluate cardiac disease at the cellular and molecular levels. The company has licensed technology from the Massachusetts General Hospital in Boston. The company's goal is to enable personalized medicine through precision diagnostics that will help the medical community diagnose disease more accurately at the earliest stages, leading to more effective treatment, management and better patient outcomes.

FluoroPharma's initial focus is the development of breakthrough PET imaging agents and is advancing two products in clinical trials for assessment of acute and chronic forms of coronary artery disease. These first in class agents have been designed to rapidly target myocardial cells. Other products in development include agents for detection of inflamed atherosclerotic plaque in peripheral arteries, agents with the potential to image brain tissue affected by Alzheimer's disease and agents that could potentially be used for imaging specific cancers. In addition to the United States, Europe and China, patents related to FluoroPharma's portfolio of imaging compounds have been issued in Japan, Canada, Australia, Finland, Portugal, Ireland and Mexico. For more information on the company, please visit: www.fluoropharma.com

Forward Looking Statements: Except for historical information contained herein, the statements in this release are forward-looking. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward looking statements in this news release include statements regarding FluoroPharma's research and development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in FluoroPharma's filings with the United States Securities and Exchange Commission. FluoroPharma undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact: Richard Moyer Cameron Associates, Inc. [phone] [e-mail] B. Prag The Del Mar Consulting Group, Inc. 858-361-1786 [e-mail]